Evidence map›Paper›PMID 32368626›Full record

ArticleClinical and translational radiation oncology2020

Efficacy and toxicity outcomes for patients treated with focal salvage high dose rate brachytherapy for locally recurrent prostate cancer.

Finbar Slevin, Samantha Hodgson, Sree Lakshmi Rodda, Peter Bownes, David Bottomley, Ese Adiotomre, Bashar Al-Qaisieh, Emma Dugdale, Oliver Hulson, Joshua Mason and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational radiation oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 4 pooled it
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 4 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Finbar SlevinLeeds Teaching Hospitals NHS Trust, Beckett Street, Leeds LS9 7TF, UK.
Samantha HodgsonLeeds Teaching Hospitals NHS Trust, Beckett Street, Leeds LS9 7TF, UK.
Sree Lakshmi RoddaLeeds Teaching Hospitals NHS Trust, Beckett Street, Leeds LS9 7TF, UK.
Peter BownesLeeds Teaching Hospitals NHS Trust, Beckett Street, Leeds LS9 7TF, UK.
David BottomleyLeeds Teaching Hospitals NHS Trust, Beckett Street, Leeds LS9 7TF, UK.
Ese AdiotomreLeeds Teaching Hospitals NHS Trust, Beckett Street, Leeds LS9 7TF, UK.
Bashar Al-QaisiehLeeds Teaching Hospitals NHS Trust, Beckett Street, Leeds LS9 7TF, UK.
Emma DugdaleLeeds Teaching Hospitals NHS Trust, Beckett Street, Leeds LS9 7TF, UK.
Oliver HulsonLeeds Teaching Hospitals NHS Trust, Beckett Street, Leeds LS9 7TF, UK.
Joshua MasonLeeds Teaching Hospitals NHS Trust, Beckett Street, Leeds LS9 7TF, UK.
Jonathan SmithLeeds Teaching Hospitals NHS Trust, Beckett Street, Leeds LS9 7TF, UK.
Ann M HenryLeeds Teaching Hospitals NHS Trust, Beckett Street, Leeds LS9 7TF, UK.
Leeds Teaching Hospitals NHS Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIsolated local recurrence of prostate cancer following primary radiotherapy or brachytherapy may be treated with focal salvage high dose rate brachytherapy, although there remains an absence of high quality evidence to support this approach.

methodsMen with prostate cancer treated consecutively between 2015 and 2018 using 19 Gy in a single fraction high dose rate brachytherapy (HDR) for locally recurrent prostate cancer were identified from an institutional database. Univariable analysis was performed to evaluate the relationship between patient, disease and treatment factors with biochemical progression free survival (bPFS).

results43 patients were eligible for evaluation. Median follow up duration was 26 months (range 1-60). Median bPFS was 35 months (95% confidence interval 25.6-44.4). Kaplan-Meier estimates for bPFS at 1, 2 and 3 years post salvage were 95.2%, 70.6% and 41.8% respectively. On univariable Cox regression analysis, only nadir PSA was significantly associated with bPFS although the majority of patients were also treated with androgen deprivation therapy. Only one late grade 3 genitourinary toxicity was observed.

conclusionFocal salvage HDR brachytherapy may provide good biochemical control with a low risk of severe toxicity. Further evaluation within clinical trials are needed to establish its role in the management of locally recurrent prostate cancer.

Indexed as

Focal salvage brachytherapyHigh dose rate brachytherapyLocal recurrenceProstate cancer

Identifiers

PMID32368626
PMCPMC7186261
OpenAlexW3013049441

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.